Can genetic polymorphisms explain the cardiovascular risk of nonsteroidal anti-inflammatory drugs?

基因多态性可以解释非甾体抗炎药的心血管风险吗？

• 批准号: 183805
• 负责人: Brophy James M
• 金额: $ 7.29万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-10-01 至 2009-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=183805&lang=en
• 关键词: Cardiovascular Safety; Gene*Drug Interaction; Genetic Polymorphisms; Genome Wide Association Studies; Nsaids; Pharmacogenomics

Anti-inflammatory drugs (NSAIDs) are widely used for fever, pain and inflammation. NSAIDs are the most common class of drug prescribed today and are associated with significant health benefits. However, recent studies have raised concerns and controversy

抗炎药（NSAID）被广泛用于发热，疼痛和炎症。NSAIDs是当今最常见的处方药，具有显著的健康益处。然而，最近的研究引起了关注和争议